AngioDynamics Inc.
| NASDAQ: ANGO | Healthcare / Medical Devices & Instruments / USA |
| 7.40 | -0.2000 | -2.63% | Vol 1.10M | 1Y Perf -64.57% |
| Oct 4th, 2023 16:00 DELAYED |
| BID | 6.84 | ASK | 7.74 | ||
| Open | 8.01 | Previous Close | 7.60 | ||
| Pre-Market | - | After-Market | 7.74 | ||
| - - | 0.34 4.59% |
| Target Price | 30.00 | Analyst Rating | Moderate Buy 1.75 | |
| Potential % | 305.41 | Finscreener Ranking | ★★★+ 51.34 | |
| Insiders Trans % 3/6/12 mo. | -/-100/-56 | Value Ranking | ★★★★ 56.13 | |
| Insiders Value % 3/6/12 mo. | -/-100/-68 | Growth Ranking | ★★★ 49.90 | |
| Insiders Shares Cnt. % 3/6/12 mo. | -/-100/-63 | Income Ranking | — - | |
| Price Range Ratio 52W % | 4.52 | Earnings Rating | Strong Sell | |
| Market Cap | 293.57M | Earnings Date | 4th Oct 2023 | |
| Alpha | -0.02 | Standard Deviation | 0.13 | |
| Beta | 0.62 |
Today's Price Range 7.178.16 | 52W Range 6.7221.88 | 5 Year PE Ratio Range -83.1058.00 |
Summary:
Neutral
| Technical Indicators: | Buy |
| Moving Averages: | Sell |
| Performance | |||
|---|---|---|---|
| 1 Week | 4.97% | ||
| 1 Month | -1.68% | ||
| 3 Months | -26.36% | ||
| 6 Months | -20.50% | ||
| 1 Year | -64.57% | ||
| 3 Years | -33.88% | ||
| 5 Years | -63.46% | ||
| 10 Years | -43.20% |
| Mngmt Effectiveness | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
ROE (5Y Avg) | -5.30 | |||
ROE last 12 Months | -8.12 | |||
ROA (5Y Avg) | -5.02 | |||
ROA last 12 Months | -6.13 | |||
ROC (5Y Avg) | -4.75 | |||
ROC last 12 Months | -6.86 | |||
Return on invested Capital Q | -1.70 | |||
Return on invested Capital Y | -5.60 | |||
Assets Turnover | 0.60 | |||
Receivables Turnover | 7.90 |
| Valuation | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| -18.30 | ||||
| 1.45 | ||||
| 1.74 | ||||
| 82.40 | ||||
| -26.70 | ||||
| -0.45 | ||||
| 9.09 | ||||
| 10.43 | ||||
| 613.20M | ||||
| Forward PE | -45.68 | |||
| PEG | - |
| Financial Strength | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| 1.10 | ||||
| 2.20 | ||||
| 0.11 | ||||
| 0.12 | ||||
| -23.90 | ||||
| Leverage Ratio | 1.30 |
| Profitability | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| 52.60 | ||||
| -10.70 | ||||
| -1.30 | ||||
| -65.90 | ||||
| -10.07 |
| Revenue | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| 327.93M | ||||
| 8.38 | ||||
| 4.02 | ||||
| -6.84 |
| Dividends | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| - | ||||
| - | ||||
| - | ||||
| - | ||||
| Payout ratio | - |
| Earnings History | Estimate | Reported | Surprise % |
|---|---|---|---|
| Q04 2023 | 0.03 | 0.02 | -33.33 |
| Q03 2023 | -0.01 | -0.03 | -200.00 |
| Q02 2023 | -0.01 | 0.01 | 200.00 |
| Q01 2023 | -0.02 | -0.06 | -200.00 |
| Q04 2022 | 0.01 | 0.01 | 0.00 |
| Q03 2022 | -0.01 | 0.03 | 400.00 |
| Q02 2022 | 0.00 | -0.02 | - |
| Q01 2022 | -0.05 | -0.02 | 60.00 |
| Earnings Per End | Estimate | Revision % | Trend |
|---|---|---|---|
| 8/2023 QR | -0.14 | -100.00 | Negative |
| 11/2023 QR | -0.08 | -700.00 | Negative |
| 5/2024 FY | -0.33 | -3 200.00 | Negative |
| 5/2025 FY | -0.16 | -200.00 | Negative |
| Next Report Date | 4th Oct 2023 |
| Estimated EPS Next Report | -0.14 |
| Estimates Count | 4 |
| EPS Growth Next 5 Years % | - |
| Volume Overview | |
|---|---|
| Volume | 1.10M |
| Shares Outstanding | 39.67K |
| Shares Float | 37.73M |
| Trades Count | 8.07K |
| Dollar Volume | 8.10M |
| Avg. Volume | 678.17K |
| Avg. Weekly Volume | 407.24K |
| Avg. Monthly Volume | 1.01M |
| Avg. Quarterly Volume | 614.87K |
AngioDynamics Inc. (NASDAQ: ANGO) stock closed at 7.6 per share at the end of the most recent trading day (a 2.15% change compared to the prior day closing price) with a volume of 456.16K shares and market capitalization of 293.57M. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Medical Devices & Instruments industry, Healthcare sector and employs 800 people. AngioDynamics Inc. CEO is James C. Clemmer.
The one-year performance of AngioDynamics Inc. stock is -64.57%, while year-to-date (YTD) performance is -44.81%. ANGO stock has a five-year performance of -63.46%. Its 52-week range is between 6.715 and 21.88, which gives ANGO stock a 52-week price range ratio of 4.52%
AngioDynamics Inc. currently has a PE ratio of -18.30, a price-to-book (PB) ratio of 1.45, a price-to-sale (PS) ratio of 1.74, a price to cashflow ratio of 82.40, a PEG ratio of -, a ROA of -6.13%, a ROC of -6.86% and a ROE of -8.12%. The company’s profit margin is -10.07%, its EBITDA margin is -1.30%, and its revenue ttm is $327.93 Million , which makes it $8.38 revenue per share.
Of the last four earnings reports from AngioDynamics Inc., there were 1 positive earnings surprise and 3 negative earnings surprise. The company has EPS estimate of $-0.14 for the next earnings report. AngioDynamics Inc.’s next earnings report date is 04th Oct 2023.
The consensus rating of Wall Street analysts for AngioDynamics Inc. is Moderate Buy (1.75), with a target price of $30, which is +305.41% compared to the current price. The earnings rating for AngioDynamics Inc. stock is Strong Sell (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).
AngioDynamics Inc. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.
AngioDynamics Inc. has a Neutral technical analysis rating based on Technical Indicators (ADX : 16.55, ATR14 : 0.32, CCI20 : 156.70, Chaikin Money Flow : 0.08, MACD : -0.17, Money Flow Index : 30.59, ROC : 4.11, RSI : 51.25, STOCH (14,3) : 94.03, STOCH RSI : 1.00, UO : 54.96, Williams %R : -5.97), Simple Moving Averages and Exponential Moving Averages.
Aggregated Insider Trades of AngioDynamics Inc. in the last 12-months were: Dave Helsel (Sold 4 633 shares of value $59 997 ), David D. Helsel (Sold 4 633 shares of value $59 997 ), James C. Clemmer (Buy at a value of $150 000), Stephen A. Trowbridge (Buy at a value of $14 967)
AngioDynamics Inc.
AngioDynamics Inc designs, manufactures and sells medical, surgical and diagnostic devices used by professional healthcare providers for the treatment of peripheral vascular disease and for use in oncology and surgical settings.
CEO: James C. Clemmer
Telephone: +1 518 795-1400
Address: 14 Plaza Drive, Latham 12110, NY, US
Number of employees: 800
